Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
4eFU9F6LqpCm1Eza
Listen
